دورية أكاديمية
Prognostic factors of pediatric ependymomas at a National Cancer Reference Center in Peru.
| العنوان: | Prognostic factors of pediatric ependymomas at a National Cancer Reference Center in Peru. |
|---|---|
| المؤلفون: | Perez-Roca E; School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru., Negreiros T; Radiotherapy Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Casavilca-Zambrano S; Pathology Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Ojeda-Medina L; Neurosurgery Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru., Díaz-Coronado R; School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru.; Pediatric Oncology Department, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru. |
| المصدر: | Frontiers in oncology [Front Oncol] 2024 Jan 17; Vol. 13, pp. 1331790. Date of Electronic Publication: 2024 Jan 17 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Background: Ependymomas are central nervous system tumors that significantly impact the quality of life and carry a high mortality rate. Both the disease itself and its treatment cause significant morbidity. At a national level in Peru, there are no reports on clinical characteristics of the disease. Methods: This retrospective study captured patient aged less than 19 years with a diagnosis of ependymoma from 2012 to 2022 at a tertiary center in Lima. Results: 85 patients were included with a median follow-up time was 51.6 months. The 5-year overall survival and progression-free survival were 55.89% (95% CI: 44.28 - 65.99) and 37.71% (95% CI: 26,21-49,16) respectively. The main prognostic factors identified were completed treatment (p=0.019), adjuvant chemotherapy (p=0.048), presence of metastasis (p=0.012), and disease recurrence (p=0.02). Conclusions: The survival of patients with ependymoma is below that reported in high-income countries. Incomplete treatment and treatment abandonment are factors that negatively impact the prognosis. Further studies are needed to identify barriers in the referral and treatment process for patients with ependymoma. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Perez-Roca, Negreiros, Casavilca-Zambrano, Ojeda-Medina and Díaz-Coronado.) |
| References: | J Intensive Care. 2015 Oct 09;3:40. (PMID: 26457187) J Glob Oncol. 2019 Oct;5:1-25. (PMID: 31682549) BMC Cancer. 2016 Apr 23;16:287. (PMID: 27108407) Mod Pathol. 2008 Feb;21(2):165-77. (PMID: 18084249) J Clin Pharm Ther. 2017 Feb;42(1):1-7. (PMID: 28045208) Pediatr Blood Cancer. 2018 Jun;65(6):e27007. (PMID: 29431252) Cancer Cell. 2015 May 11;27(5):728-43. (PMID: 25965575) Indian J Cancer. 2021 Jul-Sep;58(3):378-386. (PMID: 33402598) Indian J Med Paediatr Oncol. 2017 Oct-Dec;38(4):420-426. (PMID: 29333005) Clin Neurol Neurosurg. 2020 Dec;199:106282. (PMID: 33045626) Front Oncol. 2022 Mar 04;12:800505. (PMID: 35311130) CMAJ. 2017 Mar 27;189(12):E459-E463. (PMID: 27895146) J Neurosurg. 2009 Apr;110(4):725-9. (PMID: 19061350) Eur J Pediatr. 2012 Jan;171(1):25-32. (PMID: 21537925) J Negat Results Biomed. 2011 May 31;10:7. (PMID: 21627842) Pediatr Hematol Oncol. 2018 Feb;35(1):60-75. (PMID: 29565756) Pediatr Blood Cancer. 2012 Dec 15;59(7):1183-9. (PMID: 22949057) BMC Public Health. 2019 Dec 2;19(1):1613. (PMID: 31791308) Pediatr Blood Cancer. 2022 Oct;69(10):e29770. (PMID: 35593532) Neuro Oncol. 2016 Oct;18(10):1451-60. (PMID: 27194148) J Neurosurg. 1998 Apr;88(4):695-703. (PMID: 9525716) J Clin Oncol. 2001 Mar 1;19(5):1288-96. (PMID: 11230470) Neurol Med Chir (Tokyo). 2022 Jul 15;62(7):322-327. (PMID: 35545504) Support Care Cancer. 2021 Jul;29(7):3633-3642. (PMID: 33179135) Acta Neuropathol. 2017 Jan;133(1):5-12. (PMID: 27858204) Dan Med Bull. 2011 Jul;58(7):A4285. (PMID: 21722538) Cancer. 2022 Jan 1;128(1):47-58. (PMID: 34633681) Pediatr Blood Cancer. 2012 Mar;58(3):380-3. (PMID: 21370439) Pathol Oncol Res. 2020 Oct;26(4):2693-2701. (PMID: 32661835) J Clin Oncol. 2017 Jul 20;35(21):2364-2369. (PMID: 28640697) Brain Dev. 2010 Sep;32(8):636-41. (PMID: 19892502) J Pediatr (Rio J). 2011 Sep-Oct;87(5):425-32. (PMID: 21964994) J Neurooncol. 2012 Jan;106(2):367-75. (PMID: 21826561) Neurosurgery. 2000 Oct;47(4):879-85; discussion 885-7. (PMID: 11014428) J Neurooncol. 2011 Dec;105(3):583-90. (PMID: 21637963) J Mol Med (Berl). 2021 Aug;99(8):1101-1113. (PMID: 33903940) Trop Med Int Health. 2021 Oct;26(10):1177-1188. (PMID: 34219346) JCO Glob Oncol. 2020 Nov;6:1712-1720. (PMID: 33156716) Cent Eur Neurosurg. 2011 Aug;72(3):127-32. (PMID: 21630189) Neurooncol Pract. 2018 Nov;5(4):227-233. (PMID: 31386013) Dan Med J. 2014 Aug;61(8):A4886. (PMID: 25162445) J Neurooncol. 2013 Dec;115(3):411-9. (PMID: 24057324) Am J Dis Child. 1986 Jul;140(7):684-6. (PMID: 3012997) Cancer Epidemiol. 2021 Jun;72:101942. (PMID: 33946020) Neuro Oncol. 2023 Mar 14;25(3):593-606. (PMID: 36215122) J Neurooncol. 2013 Dec;115(3):513-20. (PMID: 24085643) Childs Nerv Syst. 2020 Sep;36(9):2047-2054. (PMID: 32157367) J Neurosurg Pediatr. 2013 Jun;11(6):673-81. (PMID: 23540528) J Clin Neurosci. 2016 Jun;28:24-30. (PMID: 26810473) Cancer Cell. 2011 Aug 16;20(2):143-57. (PMID: 21840481) Pediatr Neurosurg. 1998 Apr;28(4):215-22. (PMID: 9732252) Lancet Oncol. 2009 Mar;10(3):258-66. (PMID: 19274783) Neuro Oncol. 2022 Sep 6;24(Suppl 3):iii1-iii38. (PMID: 36066969) J Clin Oncol. 2019 Apr 20;37(12):974-983. (PMID: 30811284) Arch Dis Child. 2020 Apr;105(4):355-362. (PMID: 31653616) N Engl J Med. 1993 Jun 17;328(24):1725-31. (PMID: 8388548) BMC Cancer. 2008 Jan 21;8:15. (PMID: 18208613) J Clin Neurosci. 2012 Sep;19(9):1228-35. (PMID: 22840355) Cancer. 2004 Mar 15;100(6):1230-7. (PMID: 15022291) Lancet Oncol. 2007 Aug;8(8):696-705. (PMID: 17644039) |
| فهرسة مساهمة: | Keywords: Peru; ependymoma; outcomes; pediatric; prognosis; treatment |
| تواريخ الأحداث: | Date Created: 20240201 Latest Revision: 20240202 |
| رمز التحديث: | 20240202 |
| مُعرف محوري في PubMed: | PMC10828566 |
| DOI: | 10.3389/fonc.2023.1331790 |
| PMID: | 38298447 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2023.1331790 |